FDA Approves Moderna’s New COVID-19 Vaccine

The vaccine’s design differs from Spikevax, Moderna’s shot that has been available.

A sign marks the headquarters of COVID-19 vaccine maker Moderna in Cambridge, Mass., on April 28, 2022. Brian Snyder/Reuters

The Food and Drug Administration has approved Moderna’s next-generation COVID-19 vaccine.

The FDA licensed the vaccine for adults aged 65 and up as well as people aged 12 to 64 who have at least one condition that puts them at higher risk for severe COVID-19, the agency said on May 31. The vaccine is meant for “active immunization to prevent” COVID-19 for people who have been previously vaccinated with any COVID-19 vaccine.